Last updated on February 2018

Comparison of Post- and Pre-dilutional Hemodiafiltration in Hemodialysis Patients


Brief description of study

Hemodiafiltration (HDF) is a choice of treatment modalities for patients with end-stage renal disease. Hemodiafiltration, combining diffusion and convection, may increase removal of large and middle molecule uremic toxins comparing to conventional hemodialysis. The techniques of hemodiafiltration include pre-dilution and post-dilution according to the infusion site of substitution fluid. Post-dilution HDF is most widely used because of higher removal rate of uremic toxins. However, hemoconcentration and clotting of membrane limit its further clearance of toxins. Pre-dilution may preserve membrane permeability and maintain hemodynamic status. Although lower clearance of small molecule uremic toxins, one study in Japan showed survival benefits of pre-dilution HDF, comparing to post-dilution HDF. The aim of this study was to compare pre-dilution and post-dilution HDF in terms of their clinical and biological parameters and clearance of uremic toxins by using cross-over study design.

Detailed Study Description

  1. Study design: randomly assigned, cross-over study.
  2. Patient number: 60.
  3. Inclusion criteria: stable patients end-stage renal disease who were older than 20 years and received thrice-weekly standard hemodialysis for more than 3 months were recruited.
  4. Exclusion criteria: active systemic disease, liver cirrhosis, active malignancy, receiving immunosuppressive treatment, dialysis with temporal non-tunneled catheter, inadequate dialysis dose (single-pooled Kt/V<1.2).
  5. Methods:
     Prior to randomization, a Charlson Comorbidity Index score and baseline characteristics
     are recorded for each patient. Each patient who received HDF prior to study will
     received one-month high-flux hemodialysis with target single-pooled Kt/V>1.2 for
     washout. The baseline characteristics of each patient including dialyzer, dialysis time,
     blood flow, dialysate flow, replacement volume, pre- and post-dialysis blood pressure
     and body weight were recorded. The follow-up laboratory data will also be collected:
     predialysis C-reactive protein, blood urea nitrogen, creatinine, bicarbonate, sodium,
     potassium, uric acid, albumin, calcium, phosphate, intact parathyroid hormone,
     2-microglobulin, prolactin, fibroblast growth factor 23, 1-microglobulin, indoxyl
     sulfate, p-cresol sulfate, advance oxidation protein products, advance glycation
     product, percentage of proinflammatory monocytes; interleukin-6, tumor necrosis
     factor-, hematocrit, transferrin saturation and ferritin. Urea kinetics including kt/V,
     Urea reduction ratio and normalized protein catabolic rate are calculated. We also used
     Physical Symptoms Distress Scale for life quality measurement.

     After randomization, two group received standard prescription of pre- and post-dilution
     HDF. The prescribed convective volume per treatment of post-dilution mode is based on
     blood flow, filtration fraction and hematocrit to achieved current recommendation of 23
     liter/1.73m2. The convective volume of pre-dilution mode will be at least twice higher
     than the desired dose in post-dilution mode for each patient. After 3-month stable
     hemodiafiltration, parameters mentioned above will also be checked. Two group will be
     switched for another 3-month course and then switch again. The total following time is
     12 months.

6. Outcome: The primary objective is to compare the removal of a wide spectrum of solutes

     such as middle and protein-bound molecules. Secondary outcomes are intradialytic
     tolerance, including intradialytic hypotension, cramps and arrhythmia, and life quality
     measurements.

Clinical Study Identifier: NCT03288285

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.